A New Era In Biotech

Treatment for Xylella fastidiosa

Auxergen At A Glance

Peer-Reviewed Papers
Book Value
$ 0 M

Recent Press

Auxergen Files Patent for In-Vitro Cannabinoid Assay

Baltimore, Maryland – March 11, 2024 Auxergen announces its latest product: an in-vitro assay to measure the pharmacokinetics of THC, CBD and like cannabinoids, which promises to revolutionize the field of cannabis research and diagnostics, with application to drug discovery, design, efficacy

Read More »

Auxergen Achieves 2024 Qualified Maryland Biotechnology Status

Baltimore, Maryland – March 11, 2024 Auxergen, Inc. has achieved Qualified Maryland Biotechnology Company (QMBC) status for 2024. QMBC status provides early-stage biotechnology companies with refundable tax credits to help offset high research and development costs. Auxergen develops phage-based cures for agricultural, environmental, and

Read More »

About Us

Our Products & Technologies

Invest In Us

Investing in Auxergen is an opportunity to fuel genuine advancements addressing global challenges in agriculture and the environment. Your investment fosters the development of sustainable solutions with substantial returns driven by market demands and groundbreaking innovations.

Call Us


Mail Us